While additional pathways, aside from NAT2 genotype, have been implicated in the hepatotoxicity of isoniazid-containing anti-TB treatment regimens, it is not clear that these pathways alter isoniazid PK and thus could account for the lack of genotypic and phenotypic concordance in this study. The gene discussed is NAT2; the disease is tuberculosis.